Project Grant SB1AR083748
Award Date
9/21/23
Completion Date
8/31/25
Dollars Obligated
$400K
Funding Federal Agency
National Institute of Neurological Disorders and Stroke
Awarding Federal Agency
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
The National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), has awarded a $1,594,319 Cooperative Agreement to the University of Texas Health Science Center at Houston (UTHealth) to develop an integrated Breathing-Controlled Electrical Stimulation (BREESTIM) device and conduct a single-center randomized controlled clinical trial to examine the efficacy and safety of BREESTIM for managing neuropathic pain after spinal...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the CFDA program "Drug Use and Addiction Research Programs" (93.279), aims to demonstrate the feasibility of a novel epidural stimulation lead for the treatment of chronic arm and neck pain. Backstop Neural, Inc. will design, fabricate, and test a 16-channel, 0.2 mm thick human-sized softening paddle lead that is 10x thinner than commercially available leads. The key outcomes are...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports research on selective, epineural stimulation of peripheral nerves using interferential electrical fields. The research aims to develop methods for the selective activation of specific nerve fiber populations, which could improve the efficacy and safety of peripheral...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $3,565,780 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a groundbreaking high frequency trans-spinal magnetic stimulation (HF-TSMS) system for the non-invasive treatment of neuropathic pain. The project aims to refine the HF-TSMS technology to target neural pathways involved in...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $399,870 Project Grant to 2Morrow Inc. under the Drug Use and Addiction Research Programs (CFDA 93.279) to commercialize a digital behavioral health program for individuals with chronic pain. The funding will support hiring a Chief Commercial Officer to accelerate the dissemination and commercialization of this evidence-based digital therapeutic, which has shown strong engagement, positive feedback, and decreased...
This $231,000 Project Grant was awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The goal of the research is to determine whether electrical stimulation of distinct subregions within the insula brain structure can differentially modulate sensory and higher-order, integrative aspects of pain processing. The project will leverage rare opportunities to directly...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $378,453.00 to Emory University for a 3-year research project titled "Advancing Non-Invasive Brain Stimulation: A Comprehensive Study of Temporal Interference Mechanisms (CNS-STIM)". The project aims to bridge gaps in understanding how the innovative...
This $14.2 million project grant from the National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services, will fund research from September 2022 to August 2025 under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The Massachusetts General Hospital will investigate the mechanisms by which spinal cord stimulation reduces pain, with the goal of improving device design and patient selection. Researchers will apply specialized nerve...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $274,976 to Ecate LLC aims to develop a novel intraspinal stimulator system to restore sensation and volitional motor control in spinal cord injury patients. The project will fabricate nanopatterned stimulating electrodes coupled with custom CMOS chips to deliver spatially selective electrical stimulation to the spinal cord. This closed-loop neural interface system is intended...
This SBIR Phase II award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $2,776,138 to Neurocarrus Inc. to develop a novel biologic drug called N-001 for the management of acute nociceptive pain. The funding will be used to optimize the production and formulation of N-001, establish manufacturing standards and controls, and conduct pivotal preclinical studies to demonstrate the safety and...